Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Clementia Pharmaceuticals Inc (CMTA)

Clementia Pharmaceuticals Inc (CMTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,002,854
  • Shares Outstanding, K 38,059
  • Annual Sales, $ 0 K
  • Annual Income, $ -58,130 K
  • 60-Month Beta 0.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.08
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.80
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/08/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.53
  • Number of Estimates 2
  • High Estimate -0.51
  • Low Estimate -0.54
  • Prior Year -0.42
  • Growth Rate Est. (year over year) -26.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.75 +2.33%
on 03/19/19
26.73 -1.42%
on 04/15/19
+0.45 (+1.74%)
since 03/15/19
3-Month
12.18 +116.34%
on 01/28/19
26.73 -1.42%
on 04/15/19
+12.44 (+89.43%)
since 01/17/19
52-Week
8.10 +225.31%
on 08/07/18
26.73 -1.42%
on 04/15/19
+10.05 (+61.66%)
since 04/17/18

Most Recent Stories

More News
Retinoic Acid Receptor Gamma Market Size, Business Growth, Sales Revenue, Development Status and Forecast 2026

In 2018, the Retinoic Acid Receptor Gamma Market revenue was around US$ XX Mn and the Market share was XX%, and it will be projected to reach US$ XX Mn and XX% in 2026, with a CAGR XX% during the forecast...

VRX.TO : 30.80 (-3.33%)
CMTA : 26.35 (-0.11%)
PPGNY : 0.0097 (-96.54%)
Accomplished Financial Executive, Steve Forte, Joins Profound Medical's Board

Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) ("Profound" or the "Company"), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging ("MRI"),...

PRFMF : 0.8190 (-11.59%)
CMTA : 26.35 (-0.11%)
Global Retinoic Acid Receptor Gamma Market Insights, Forecast to 2019 Analysis by Application, Size, Production, Market Share, Consumption, Trends and Forecast 2025

The market size of Retinoic Acid Receptor Gamma is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will...

VRX.TO : 30.80 (-3.33%)
CMTA : 26.35 (-0.11%)
PPGNY : 0.0097 (-96.54%)
Ipsen Completes Acquisition of Clementia Pharmaceuticals

--Transaction reinforces Ipsen's strong commitment to providing life-altering treatments to patients with high unmet medical needs

IPN : 34.71 (-0.54%)
CMTA : 26.35 (-0.11%)
IPSEY : 25.0900 (+0.97%)
Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.

Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) ("Clementia" or the "Corporation") is pleased to announce that the Quebec Superior Court issued earlier today a final order approving the previously announced...

CMTA : 26.35 (-0.11%)
Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A.

Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) ("Clementia" or the "Corporation") is pleased to announce that its shareholders have approved the previously announced statutory plan of arrangement under...

CMTA : 26.35 (-0.11%)
2019 Global Retinoic Acid Receptor Gamma Market Research Report with Industry Forecast 2025 and Outlook

The global Retinoic Acid Receptor Gamma market is valued at million US$ in 2018 is expected to reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.This report focuses on Retinoic...

VRX.TO : 30.80 (-3.33%)
CMTA : 26.35 (-0.11%)
MERGER ALERT - CMTA and ONCE: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies

The following statement is being issued by Levi & Korsinsky, LLP:

ONCE : 104.77 (-0.83%)
CMTA : 26.35 (-0.11%)
Lifshitz & Miller LLP Announces Investigation of Amarin Corporation plc, Clementia Pharmaceuticals Inc., CVS Health Corporation, Diplomat Pharmacy, Inc., GTx, Inc., Multi-Color Corporation, Osiris Therapeutics, Inc., and The Kraft Heinz Company

Amarin Corporation plc (AMRN)

CVS : 64.06 (+0.25%)
AMRN : 16.71 (-0.24%)
KHC : 29.25 (+0.76%)
CMTA : 26.35 (-0.11%)
OSIR : 18.99 (unch)
LABL : 50.01 (+0.08%)
DPLO : 5.65 (-5.68%)
GTXI : 1.20 (unch)
Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Clementia, Multi-Color, and GTx on Behalf of Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Clementia Pharmaceuticals Inc., Multi-Color Corporation, and GTx, Inc. Additional information...

CMTA : 26.35 (-0.11%)
LABL : 50.01 (+0.08%)
GTXI : 1.20 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade CMTA with:

Business Summary

Clementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. The company's lead product consists of palovarotene, a novel RAR' agonist, to treat fibrodysplasia ossificans progressiva,...

See More

Key Turning Points

2nd Resistance Point 26.85
1st Resistance Point 26.60
Last Price 26.35
1st Support Level 26.19
2nd Support Level 26.03

See More

52-Week High 26.73
Last Price 26.35
Fibonacci 61.8% 19.61
Fibonacci 50% 17.42
Fibonacci 38.2% 15.22
52-Week Low 8.10

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar